Medivir AB (publ)

the Medivir Q3 report. Today is a very exciting day. In addition to sharing the great progress in continued momentum in the ongoing Fostrox program. It is with great enthusiasm.

We look forward to providing an in-depth update on the promising signals of clinical benefit we're seeing with the Fostrox-Linvima combination in primary liver cancer. And we will also touch what that means for our plans as we move ahead. Before we go into the details, as always, important information and this in detail you will find when we post the presentation on our website. My name is Jens Lindberg and I am the CEO of Medivir. Today I am joined by our Chief Medical Officer Pia Baumann and our CFO Magnus Kristensen. Our Chief Scientific Officer Fredrik Öberg is also here with us for the Q&A session towards the end. But most importantly, we are joined by Dr. Jeff Evans from Glasgow, Scotland, who is principal investigator in the ongoing Fostrox Lendvima study. Jeff is joining us via link today from Scotland, where he is working clinically today, and he will be putting the Fostrox Lendvima data into clinical context. But before we go into the details of the data we're seeing in the study, a brief update on the overall Q3 results for Medivir. So, Magnus.

Thank you, Jens. I will briefly comment on the Q3 report from a financial viewpoint. All the numbers you see are a million SEK.